Retatrutide – 10 mg – Driada – exp. 2028 (incl. water and syringes) (shipped from Spain)

Description This peptide comes together with a 1ml ampoule of water, 10 insulin syringes and 10 alcohol pads. Retatrutide (LY3437943) is an innovative peptide under development by Eli Lilly for therapy in overweight, obesity, and type 2 diabetes (T2D). Functioning as a triple-agonist, the peptide has the ability to simultaneously engage with three key receptors: glucagon (GCGR), as well as the receptors for the incretin hormones GLP-1 (GLP-1R) and GIP (GIPR). Data from phase 1b and phase 2 trials reveal that retatrutide is notably effective in promoting weight loss and enhancing glycemic control in patients with type 2 diabetes (T2D). Furthermore, a substudy within one of the phase 2 trials highlights its effectiveness in reducing liver fat in individuals with obesity and metabolic-dysfunction-associated steatohepatitis (MASH). Retatrutide Dose: Initiated at 2mg/weekly for the first four weeks of the study period, followed by an increase to 4mg/weekly in weeks 5-8, 8mg/weekly in weeks 9-12, 12mg/weekly in weeks 13 and beyond. Frequency: Once weekly; subcutaneously. Cycle Duration: up to 48 weeks. Dosage should never exceed 12mg/weekly. Missed doses should be administered within 5 days or skipped, and consequent doses should taken according to the initial schedule